Noscapine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
Noscapine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
Noscapine | hsa00480 | Glutathione metabolism | 3.02E-02 | 1 | P48506 | GCLC | More | |
Noscapine | hsa00564 | Glycerophospholipid metabolism | 2.52E-02 | 3 | P48651, Q9Y6K0, Q86XP1 | PTDSS1, CEPT1, DGKH | More | |
Noscapine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
Noscapine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
Noscapine | hsa00600 | Sphingolipid metabolism | 4.56E-02 | 3 | Q9BX95, Q06136, P06280 | SGPP1, FVT1, GLA | More | |
Noscapine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
Noscapine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Noscapine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
Noscapine | hsa00983 | Drug metabolism - other enzymes | 3.10E-02 | 2 | P20839, Q16772 | IMPDH1, GSTA3 | More | |
Noscapine | hsa01100 | Metabolic pathways | 2.79E-02 | 14 | Q9Y234, Q16772, Q02153, P20839, O94777, Q9Y6K0, Q86XP1, Q9UHK6, Q86VZ5, P48651, Q969G6, P14927, Q06055, Q9NVH6 | LIPT1, GSTA3, GUCY1B3, IMPDH1, DPM2, CEPT1, DGKH, AMACR, SGMS1, PTDSS1, RFK, UQCRB, ATP5G2, TMLHE | More | |
Noscapine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
Noscapine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
Noscapine | hsa02010 | ABC transporters | 2.43E-03 | 3 | P45844, P08183, Q99758 | ABCG1, ABCB1, ABCA3 | More | |
Noscapine | hsa03013 | RNA transport | 1.91E-02 | 9 | P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | |
Noscapine | hsa03018 | RNA degradation | 3.02E-02 | 1 | Q13901 | C1D | More | |
Noscapine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
Noscapine | hsa03420 | Nucleotide excision repair | 4.91E-02 | 2 | P07992, P54727 | ERCC1, RAD23B | More | |
Noscapine | hsa04064 | NF-kappa B signaling pathway | 2.83E-02 | 8 | P10415, Q13489, O00463, Q13546, Q9UDY8, Q13077, Q16548, P24522 | BCL2, BIRC3, TRAF5, RIPK1, MALT1, TRAF1, BCL2A1, GADD45A | More | |
Noscapine | hsa04071 | Sphingolipid signaling pathway | 2.76E-05 | 9 | P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, Q16539, P10415, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, MAPK14, BCL2, GAB2 | More | |
Noscapine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
Noscapine | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
Noscapine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
Noscapine | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | |
Noscapine | hsa04216 | Ferroptosis | 4.50E-02 | 1 | P48506 | GCLC | More | |
Noscapine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
Noscapine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
Noscapine | hsa04330 | Notch signaling pathway | 4.91E-02 | 2 | P49768, P78504 | PSEN1, JAG1 | More | |
Noscapine | hsa04340 | Hedgehog signaling pathway | 1.80E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | |
Noscapine | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
Noscapine | hsa04520 | Adherens junction | 4.91E-02 | 2 | P07947, P19784 | YES1, CSNK2A2 | More | |
Noscapine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
Noscapine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
Noscapine | hsa04613 | Neutrophil extracellular trap formation | 8.84E-05 | 17 | O60603, P05164, P08246, Q9UM07, Q92769, P04908, Q6FI13, Q93077, P62807, O60814, P68431, Q15080, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC2, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | |
Noscapine | hsa04622 | RIG-I-like receptor signaling pathway | 1.63E-02 | 2 | Q12933, P10145 | TRAF2, IL8 | More | |
Noscapine | hsa04650 | Natural killer cell mediated cytotoxicity | 3.52E-05 | 10 | P16298, P50591, P01375, P20963, Q02750, Q13241, P26718, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, CD247, MAP2K1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
Noscapine | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
Noscapine | hsa04668 | TNF signaling pathway | 5.53E-03 | 9 | P01375, O00463, Q13546, Q13489, Q16539, P18848, P19875, Q13077, P14780 | TNF, TRAF5, RIPK1, BIRC3, MAPK14, ATF4, CXCL2, TRAF1, MMP9 | More | |
Noscapine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
Noscapine | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
Noscapine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
Noscapine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
Noscapine | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | |
Noscapine | hsa04924 | Renin secretion | 3.43E-03 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | |
Noscapine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
Noscapine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
Noscapine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
Noscapine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Noscapine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
Noscapine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | |
Noscapine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
Noscapine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
Noscapine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
Noscapine | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Noscapine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
Noscapine | hsa05144 | Malaria | 1.25E-04 | 7 | P68871, O60603, P01375, P05107, P35443, P10145, P26718 | HBB, TLR2, TNF, ITGB2, THBS4, IL8, KLRK1 | More | |
Noscapine | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
Noscapine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
Noscapine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | |
Noscapine | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | |
Noscapine | hsa05202 | Transcriptional misregulation in cancer | 1.61E-03 | 13 | Q15532, P41732, P14780, P27930, Q16548, Q13489, Q13077, P35226, P05164, P08246, Q9C0K0, Q92769, P24522 | SS18, TSPAN7, MMP9, IL1R2, BCL2A1, BIRC3, TRAF1, BMI1, MPO, ELA2, BCL11B, HDAC2, GADD45A | More | |
Noscapine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | |
Noscapine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Noscapine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
Noscapine | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | |
Noscapine | hsa05217 | Basal cell carcinoma | 2.01E-02 | 4 | Q13635, P04628, Q9UJU2, P24522 | PTCH1, WNT1, LEF1, GADD45A | More | |
Noscapine | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | |
Noscapine | hsa05321 | Inflammatory bowel disease | 3.02E-03 | 4 | O60603, P01375, Q14765, Q9UL17 | TLR2, TNF, STAT4, TBX21 | More | |
Noscapine | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Noscapine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Noscapine | hsa05332 | Graft-versus-host disease | 5.46E-05 | 5 | P48023, P10747, P01375, P26715, Q13241 | FASLG, CD28, TNF, KLRC1, KLRD1 | More | |
Noscapine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |